| Name | Title | Contact Details |
|---|
Novalar Pharmaceuticals Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Greatbatch, Inc. provides top-quality technologies to industries that depend on reliable, long-lasting performance through its brands Greatbatch Medical, Electrochem and QiG Group.
Imaging3, Inc. is a Burbank, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, and listed on the Toronto Stock Exchange (TMD) and on NASDAQ in the United States (TMDI). Titan is focused on the design, development and commercialization of novel advanced robotic surgical technologies such as SPORT(TM) Surgical System. Titan`s SPORT Surgical System is a versatile single incision advanced robotic platform that features state-of the-art multi-articulated instruments with unique replaceable tips, 3D visualization on High Definition flat-screen monitor, highly ergonomic open workstation with natural surgeon interface and a single low-profile patient cart for ease of set up that enables broad applications of single and multi-quadrant surgeries. The SPORT Surgical System`s smart design elements are geared with the specific goals of delivering superior clinical capabilities and unparalleled OR efficiency at the operating costs similar to Laparoscopic Surgery in mind. Titan Medical Inc. is focused on delivering the promise of Robotic Surgery Optimized. SPORT Surgical System is currently not cleared by FDA or doesn`t have the CE mark.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.